-
Looking at PD-(L)1×TGF-β from ESMO in 2021
Time of Update: 2021-09-18
Figure: M7824 mechanism of action Data source: Merck (2) SHR-1701 is an anti-PD-L1×TGF-βRⅡ bifunctional fusion protein independently developed by Hengrui Medicine, which can block the PD-1/PD-L1 pathway and neutralize TGF- in the tumor microenvironment.
-
"Snoop" on the KRAS G12C patents of major companies
Time of Update: 2021-09-18
However, the author found that there are two types of core structures that are very similar to the two patent ideas of AZ (Figure 11): directly use the AZ design strategy on the basis of the AMG510 skeleton .
-
Hebo Pharmaceutical Announces Positive Results of Phase I Study of New Generation Anti-CTLA-4 Antibody HBM4003
Time of Update: 2021-09-18
Hebo Pharmaceutical announced that its self-developed product HBM4003 has achieved positive results in a phase I dose-climbing clinical trial for patients with advanced solid tumors in Australia .
Main results of the Phase I study(I) The 4 Australian centers of the Phase I study enrolled 20 subjects with advanced solid tumors.
-
Chongqing pharmaceutical company will win 200 million oral hypoglycemic drugs
Time of Update: 2021-09-13
Data source: official website of the State Food and Drug Administration, Mi Nei. com database Note: Meinenet China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories .
-
Kelun will win the first imitation of 300 million large varieties
Time of Update: 2021-09-13
In 2020, the total terminal sales of Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 300 million yuan .
In 2020, the total terminal sales of Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 300 million yuan .
-
Joincare's recombinant new coronavirus fusion protein vaccine enters phase III clinical trials
Time of Update: 2021-09-13
On August 27, Joincare Pharmaceuticals issued an announcement stating that the “recombinant new coronavirus fusion protein vaccine” developed by Livzonumab, a holding subsidiary of Livzon Group, has launched a global phase III clinical trial .
-
2 billion anti-gout "Brother One" fights fiercely!
Time of Update: 2021-09-13
According to Mi Nei. com, in 2020, the total sales of febuxostat tablets in the terminals of public medical institutions in China and physical pharmacies in cities in China will reach nearly 2 billion yuan .
-
Shanghai Pharmaceuticals Class 1 new drugs hit the 100 billion market
Time of Update: 2021-09-13
Sales of terminal anti-tumor drugs in public medical institutions in China (unit: ten thousand yuan) Source: Mi Nei. com, China's public medical institutions terminal competition pattern Since the beginning of this year, Shanghai Pharmaceuticals has received clinical approval for 5 new class 1 drugs, including SPH6516 tablets, SPH3127 tablets, SPH5030 tablets, recombinant anti-CD20 humanized monoclonal antibody injection and TK216 injection .
-
The battle against tuberculosis: from Delamani, Bedaquinoline, Pretomanid to my country's first self-developed Serdapyridine
Time of Update: 2021-09-13
In the study of Bedaquiline and delamanid in combination for treatment of drugresistant tuberculosis, researchers showed a cohort report, from January 2016 to August 2016, a total of 28 cases of multi-drug resistant tuberculosis from Armenia, India and South Africa The patient was treated with Bedaquinoline combined with Dramani .
-
China Biopharmaceuticals accelerates the international innovation layout and officially launches X-LAB
Time of Update: 2021-09-13
Mao Li said that in order to achieve this strategic plan, the group will establish a high-level international scientific advisory committee, including internationally renowned experts in key fields and experienced former leaders of multinational pharmaceutical companies .
-
Over 100 million in annual sales!
Time of Update: 2021-09-13
Data source: Mi Neiwang database, NMPA Medical Network News on August 27 Recently, Hengrui Medicine has entered the administrative examination and approval stage with the imitation of the 3 types of poppy iodized oil injection, which is expected to be approved and deemed to have been reviewed .
-
Sinopharm submitted the vaccine replant plan and Pfizer's third injection will be approved. How strong is the booster injection?
Time of Update: 2021-09-12
On August 25, the Israeli Ministry of Health announced that the R value of the infection rate for people over 60 years old who had received the third injection dropped below 1, which means that the risk of infection for patients is decreasing and the epidemic is subtracting; however, on the other hand, The number of infections in Israel continues to increase .
-
Yuandong's first class 1 new biological drug has come to attack the field of anesthesia and analgesia
Time of Update: 2021-09-12
Figure 2: The clinical situation of yogliptin tablets Source: China Drug Clinical Trial Publicity Library of Meinenet Eutagliptin tablets are a new class 1 chemical drug independently developed by the company.
-
CP Tianqing will win the first imitation of $1.5 billion star drug
Time of Update: 2021-09-12
According to data from Meinenet, since 2018, Chia Tai Tianqing Pharmaceuticals has approved 9 new classified anti-tumor and immunomodulators for production, and 5 of them are the first imitations .
-
CDK1: Occupies an important site of signal transduction, clinically refers to pancreatic cancer & glioma!
Time of Update: 2021-09-12
Therefore, relying on the important sites of the signal pathway, the development of CDK1 inhibitors has received extensive attention, especially its clinical research is more directed towards pancreatic cancer and glioma, making researchers full of expectations for the potential of this target .
-
The secret of channel growth, Trax helps pharmaceutical companies implement the perfect store strategy
Time of Update: 2021-09-11
Focusing on the customer’s difficulties in implementing the perfect store implementation, Trax uses advanced image recognition and data analysis to help the customer shorten the data collection time, simplify the data collection process, improve the data utilization capabilities, and ultimately achieve the rapid growth of the perfect store ratio and in-store Both sales performance and consumer satisfaction improved .
-
Qilu will win over $2 billion star drug to sprint for the first time in China
Time of Update: 2021-09-04
Production status of Apster tablets Source: Mi Nei Net Consistency Evaluation Database Amgen’s Apster tablets were approved for import in August 2021.
Production status of Apster tablets Source: Mi Nei Net Consistency Evaluation Database Amgen’s Apster tablets were approved for import in August 2021.
-
Soaring 1175% oral hypoglycemic drug Kelun will be approved
Time of Update: 2021-09-04
According to data from Mi Nei. com, the market size of SGLT-2 inhibitors in China's public medical institutions and Chinese urban physical pharmacies will exceed 1 billion yuan in 2020 , a year-on-year increase of 232.
-
Nanjing Chia Tai Tianqing hits the first imitation of $500 million anti-tumor drug
Time of Update: 2021-09-04
According to data from Meinenet, the global sales of Regorafenib in 2020 will reach 475 million euros (approximately US$556 million), and the total sales of Regorafenib in the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities exceed 600 million yuan.
-
Qilu shows off!
Time of Update: 2021-08-29
Sales of terminal esmolol injection in public medical institutions in China (unit: ten thousand yuan) Source: Mi Nei. com, China's public medical institutions terminal competition pattern At present, 10 companies in the domestic market have approved the production of esmolol hydrochloride injection, including Qilu Pharmaceutical, China Resources Shuanghe, Osaikang, Lukang Pharmaceutical , Lingkang Pharmaceutical, and Baxter Medical .
